IRIS PubliCatt

Criscuolo, Marianna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.573
EU - Europa 2.247
AS - Asia 492
SA - Sud America 28
AF - Africa 13
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 5.367
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.561
DE - Germania 846
SE - Svezia 501
CN - Cina 354
IT - Italia 196
UA - Ucraina 184
IE - Irlanda 126
PL - Polonia 110
FR - Francia 109
IN - India 67
FI - Finlandia 51
GB - Regno Unito 41
TR - Turchia 18
BE - Belgio 15
NL - Olanda 15
BR - Brasile 12
CI - Costa d'Avorio 11
JP - Giappone 11
AU - Australia 10
CA - Canada 9
ES - Italia 8
IR - Iran 8
NO - Norvegia 7
RU - Federazione Russa 7
TH - Thailandia 7
VN - Vietnam 7
CO - Colombia 6
CZ - Repubblica Ceca 6
SG - Singapore 6
CH - Svizzera 5
AT - Austria 4
CL - Cile 4
AR - Argentina 3
HU - Ungheria 3
KR - Corea 3
MX - Messico 3
RO - Romania 3
EU - Europa 2
HK - Hong Kong 2
HR - Croazia 2
ID - Indonesia 2
IL - Israele 2
MD - Moldavia 2
MY - Malesia 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
BG - Bulgaria 1
BO - Bolivia 1
DK - Danimarca 1
EC - Ecuador 1
EG - Egitto 1
GR - Grecia 1
IS - Islanda 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
SO - Somalia 1
UY - Uruguay 1
Totale 5.367
Salva come PNG Salva come JPEG
Città #
Chandler 559
Ashburn 170
Jacksonville 138
Dublin 120
San Mateo 112
Ann Arbor 109
Warsaw 106
Dearborn 96
Woodbridge 94
Houston 93
Nanjing 93
Wilmington 79
New York 63
Fairfield 56
Milan 49
Boston 45
Bremen 44
Nürnberg 40
Cattolica 38
Seattle 38
Redwood City 37
Nanchang 36
Princeton 34
Lawrence 33
Chicago 31
Los Angeles 26
Beijing 25
Hangzhou 23
Marseille 23
Leawood 20
Shenyang 20
Mountain View 19
Cambridge 18
Munich 18
Shanghai 18
Kunming 17
Chatsworth 16
Redmond 16
Brussels 15
Auburn Hills 14
Augusta 14
Rome 14
Falls Church 13
Izmir 13
Pune 13
Zhengzhou 13
Hebei 12
Abidjan 11
Changsha 11
Norwalk 11
Tianjin 11
Boardman 10
Hefei 10
Jiaxing 10
Guangzhou 9
Jinan 9
University Park 9
Simi Valley 8
São Paulo 8
Washington 8
Lappeenranta 7
Philadelphia 7
Brooklyn 6
Edinburgh 6
Enterprise 6
Hanoi 6
London 6
Fremont 5
Lanzhou 5
Busto Arsizio 4
Changchun 4
Costa Mesa 4
Helsinki 4
Kraków 4
Medellín 4
Sydney 4
Vancouver 4
Andover 3
Berlin 3
Budapest 3
Esslingen am Neckar 3
Groningen 3
Gunzenhausen 3
Kish 3
Kocaeli 3
Madrid 3
Mcallen 3
Monmouth Junction 3
Mumbai 3
New Delhi 3
Ningbo 3
Oslo 3
Phoenix 3
Putian 3
Richardson 3
Rochester 3
Taizhou 3
Zurich 3
Örebro 3
Amsterdam 2
Totale 2.972
Salva come PNG Salva come JPEG
Nome #
Fanconi anemia gene variants in therapy-related myeloid neoplasms 250
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 158
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 130
Why methylation is not a marker predictive of response to hypomethylating agents 130
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 129
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 127
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 127
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 126
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. 125
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 119
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 115
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 114
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 108
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 108
Primary plasma cell leukemia followed by testicular plasmacytoma 106
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 105
Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency 103
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 101
Similarities and differences between therapy-related and elderly acute myeloid leukemia 99
Epigenetic changes in therapy-related MDS/AML 98
in Higher-Risk Myelodysplastic Syndromes and Low Blast Count Acute Myeloid Leukemia: Results of the BMT-AZA Prospective Study 98
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 97
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 97
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 96
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 95
Outcome of therapy-related myeloid neoplasms treated with azacitidine 90
Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report 85
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 83
Clonal evolution in therapy-related neoplasms 82
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 76
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 76
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 75
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 74
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 71
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders 71
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 69
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 68
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 65
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. 63
Aggressive Light Chain Myeloma Originating a Double Peak on Serum Electrophoresis: What's Underneath? 63
Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey 61
Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis 60
Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin 58
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 58
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 57
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 54
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study 53
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome 53
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders 53
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 52
Therapy-related myeloid neoplasms: Clinical perspectives 51
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 51
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up: The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry 50
A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group 49
In vitro Effect of Eltrombopag Alone and in Combination With Azacitidine on Megakaryopoiesis in Patients With Myelodysplastic Syndrome 48
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS 46
The validity of the fifth and the 10th Body Mass Index percentile as weight cut-offs for anorexia nervosa in adolescence: No evidence from quantitative and network investigation of psychopathology 45
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 42
Extramedullary Involvement in Acute Myeloid Leukemia. A Single Center Ten Years' Experience 42
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper 41
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 40
Fungaemia in haematological malignancies: SEIFEM-2015 survey 40
Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study 40
Systemic mastocytosis revisited with an emphasis on skeletal manifestations 40
Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM-12B study) 39
Disseminated geosmithia argillacea infection in a patient with ph-positive acute lymphoblastic leukemia. Case report and literature review 33
Mastocytosis: One Word for Different Diseases 28
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry 21
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 16
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 14
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 12
Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope 9
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry 5
A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation 3
SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report 2
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis 2
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022 2
Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients 2
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review 2
Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey 2
Totale 5.448
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.729
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.729
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201969 0 0 0 0 0 0 0 0 0 0 46 23
2019/2020869 164 36 56 63 115 138 51 23 60 63 43 57
2020/2021637 27 51 15 46 65 82 83 18 56 53 123 18
2021/2022689 64 39 8 29 51 35 13 122 37 72 94 125
2022/20231.446 185 206 122 267 77 180 50 110 157 20 52 20
2023/2024552 37 185 27 27 29 131 60 15 11 26 4 0
Totale 5.448